We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
+58.74%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$447M
AUM Growth
+$69.6M
Cap. Flow
-$23.8M
Cap. Flow %
-5.33%
Top 10 Hldgs %
68.5%
Holding
29
New
4
Increased
4
Reduced
6
Closed
3

Top Buys

1
PRAX icon
Praxis Precision Medicines
PRAX
+$15.3M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$11.8M
3
SLN
Silence Therapeutics
SLN
+$10.4M
4
ADVM
Adverum Biotechnologies
ADVM
+$8.24M
5
TYRA icon
Tyra Biosciences
TYRA
+$6.3M

Top Sells

1
ELVN icon
Enliven Therapeutics
ELVN
+$20.3M
2
IRON icon
Disc Medicine
IRON
+$17M
3
VKTX icon
Viking Therapeutics
VKTX
+$15.5M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.3M
5
SPRB
Spruce Biosciences
SPRB
+$6.93M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
1
Enliven Therapeutics
ELVN
$3.63B
$67.5M 15.11%
3,835,975
-1,325,000
-26% -$20.3M
TRDA icon
2
Entrada Therapeutics
TRDA
$267M
$62.5M 13.99%
4,408,379
– –
DNTH icon
3
Dianthus Therapeutics
DNTH
$5.21B
$37.3M 8.34%
1,242,029
-230,235
-16% -$5M
MRUS
4
DELISTED
Merus
MRUS
$24.7M 5.53%
548,825
+27,294
+5% +$1.11M
CLDX icon
5
Celldex Therapeutics
CLDX
$2.78B
$20.9M 4.67%
497,270
– –
PRAX icon
6
Praxis Precision Medicines
PRAX
$8.59B
$20.7M 4.65%
+340,000
New +$15.3M
VKTX icon
7
Viking Therapeutics
VKTX
$4.22B
$19.5M 4.36%
237,560
-347,440
-59% -$15.5M
PHVS icon
8
Pharvaris
PHVS
$2.35B
$18.4M 4.13%
797,600
– –
BHVN icon
9
Biohaven
BHVN
$2.13B
$17.5M 3.92%
319,972
-80,000
-20% -$3.96M
RNAM
10
DELISTED
Avidity Biosciences
RNAM
$17M 3.8%
665,555
– –
TYRA icon
11
Tyra Biosciences
TYRA
$1.88B
$15.4M 3.45%
939,298
+384,319
+69% +$6.3M
VOR icon
12
Vor Biopharma
VOR
$940M
$15.1M 3.38%
318,086
– –
MLTX icon
13
MoonLake Immunotherapeutics
MLTX
$1.59B
$14.2M 3.18%
282,313
-20,317
-7% -$1.1M
CNTA
14
DELISTED
Centessa Pharmaceuticals
CNTA
$14.1M 3.15%
+1,245,000
New +$11.8M
VRDN icon
15
Viridian Therapeutics
VRDN
$1.99B
$12.9M 2.89%
736,595
+150,000
+26% +$2.91M
SLN
16
Silence Therapeutics
SLN
$516M
$10.3M 2.3%
+476,200
New +$10.4M
ANAB icon
17
AnaptysBio
ANAB
$1.6B
$8.06M 1.8%
357,733
– –
ZNTL icon
18
Zentalis Pharmaceuticals
ZNTL
$325M
$7.72M 1.73%
490,000
– –
ADVM
19
DELISTED
Adverum Biotechnologies
ADVM
$7.66M 1.71%
+541,666
New +$8.24M
RLYB icon
20
Rallybio
RLYB
$84.7M
$6.72M 1.5%
453,841
– –
GHRS icon
21
GH Research
GHRS
$2B
$6.1M 1.37%
572,665
+168,261
+42% +$1.34M
SCPH
22
DELISTED
scPharmaceuticals
SCPH
$6.03M 1.35%
1,200,647
– –
MRSN
23
DELISTED
Mersana Therapeutics
MRSN
$5.85M 1.31%
52,200
– –
COGT icon
24
Cogent Biosciences
COGT
$6.48B
$5.31M 1.19%
790,440
– –
QTTB icon
25
Q32 Bio
QTTB
$258M
$4.29M 0.96%
251,994
-2
-0% -$28
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
BWM
BNC Wealth Management Beaverton, Oregon $360M AUM 49.82% 1-Year Est. Return
LC
Legacy CG Plano, Texas $360M AUM 17.55% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
PWM
Proathlete Wealth Management Boca Raton, Florida $361M AUM 17.13% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return

5AM Venture Management's Q1 2024 Portfolio in Review

As of Q1 2024, 5AM Venture Management held 29 positions worth $447M, up 18% from $377M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

5AM Venture Management withdrew a net $23.8M in Q1 2024, closing 3 positions and reducing 6 holdings. Its most notable exit was Disc Medicine, an estimated $17M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, 5AM Venture Management opened a new position in Praxis Precision Medicines worth $20.7M.

  • 5AM Venture Management's largest Q1 2024 buy was Praxis Precision Medicines: 340,000 shares worth $20.7M.
  • 5AM Venture Management added most to Tyra Biosciences in Q1 2024, an estimated $6.3M increase.
  • 5AM Venture Management's biggest Q1 2024 reduction was Enliven Therapeutics, cutting an estimated $20.3M.
  • 5AM Venture Management fully exited Disc Medicine in Q1 2024, selling an estimated $17M.
  • 5AM Venture Management's ten largest holdings make up 68% of its $447M portfolio in Q1 2024.
  • 5AM Venture Management opened 4 new positions and closed 3 in Q1 2024.
  • 5AM Venture Management's portfolio value rose 18% quarter-over-quarter to $447M.

Based on 5AM Venture Management's 13F filing for Q1 2024, filed 15 May 2024.